Author： Keck Jr Paul E McElroy Susan L
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.4, 2003-04, pp. : 655-662
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This paper reviews the clinical pharmacology, efficacy and safety of the novel antipsychotic drug aripiprazole. All published citations regarding aripiprazole were reviewed using a Medline® search (completed for citations through mid-year, 2002). In addition, abstracts from recent scientific meetings presenting data not yet published (nor peer-reviewed) were reviewed. Aripiprazole has a unique mechanism of action as a dopamine D2 partial agonist, serotonin 5-HT1A partial agonist and serotonin 5-HT2A antagonist. Like other new antipsychotics, aripiprazole has the profile of an atypical agent, with efficacy in the treatment of positive and negative symptoms of psychosis as well as mood symptoms, a low rate of neurological side effects and no significant adverse effect on serum prolactin concentrations. In addition, aripiprazole was not associated with significant weight gain or QTc prolongation in both acute and long-term treatment trials.
Related content
Access to resources
Recommend
By Assié Marie-Bernadette Bardin Laurent Auclair Agnès Consul-Denjean Nathalie Sautel François Depoortère Ronan Newman-Tancredi Adrian
Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 375, Iss. 4, 2007-06 ,pp. :
By Natesan Sridhar Reckless Greg Barlow Karen Odontiadis John Nobrega José Baker Glen George Susan Mamo David Kapur Shitij
Psychopharmacology, Vol. 199, Iss. 2, 2008-08 ,pp. :
By Wood M.D. Boyfield I. Nash D.J. Jewitt F.R. Avenell K.Y. Riley G.J.
European Journal of Pharmacology, Vol. 407, Iss. 1, 2000-10 ,pp. :